Effects of Additional Administration of a Selective Inhibitor of Sodium Glucose co-transporter-2 Inhibitor on the Glycemic Control in Japanese Type 2 Diabetes Mellitus Patients Receiving Treatment with a Dipeptidyl Peptidase-4 Inhibitor

Abstract

We conducted this study to determine whether additional administration sodium-glucose co-transporter 2 (SGLT2) inhibitor might provide further improvement of glycemic control and also to explore any advantages in Japanese type 2 diabetes patients showing relatively good glycemic control under treatment dipeptidyl peptidase-4 (DPP-4) inhibitors. We divided the patients in two groups, MT group and CT group. The MT group were continued on the DPP-4 inhibitor treatment for 6-months, and CT group were additionally administered an SGLT2 inhibitor treatment for 6-months. The MT group showed a significant decrease of hemoglobin A1c (HbA1c), but a significant increase of body weight, body mass index and serum uric acid, compared to the baseline values, while the CT group showed a significant decrease of HbA1c, body weight, BMI, and serum uric acid, and also a significant increase of serum HDL-cholesterol and decrease of serum triglyceride levels. Furthermore, this group showed a significant decrease of serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl transpeptidase (γ-GTP), which are markers of liver function. These results suggest that the combination therapy is useful, in particular, for the treatment of type 2 diabetes mellitus patients with hyperlipidemia and liver dysfunction. Among the SGLT2 inhibitors added to the DPP-4 inhibitor treatment, the decreases of serum levels of AST, ALT and γ-GTP were particularly significant in the group receiving luseogliflozin, suggesting that the combination of a DPP-4 inhibitor with luseogliflozin is particularly effective for the treatment of type 2 diabetes mellitus patients with liver dysfunction.

Keywords

sodium-glucose co-transporter 2 inhibitor - dipeptidyl peptidase-4 inhibitor - type 2 diabetes, hemoglobin A1c

• References

• 1 Kim YG, Hahn S, Oh TJ. et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: A systematic review and meta-analysis. Diabetologia 2013; 56: 696-708
• 2 Esposito K, Cozzolino D, Bellastella G. et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of<7% in type 2 diabetes: Meta-analysis of randomized controlled trials. Diabetes Obes Metab 2011; 13: 594-603
• 3 Wright EM. Glucose transport families SLC5 and SLC50. Mol Aspects Med 2013; 34: 183-196
• 4 Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011; 91: 733-794
• 5 DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia. Diabetes Obes Metab 2012; 14: 5-14
• 6 Shah Z, Kampfrath T, Deiuliis JA. et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011; 124: 2338-2349
• 7 Monami M, Lamanna C, Desideri CM. et al. DPP-4 inhibitors and lipids: Systematic review and meta-analysis. Adv Ther 2012; 29: 14-25
• 8 Seino Y, Sasaki T, Fukatsu A. et al. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin 2014; 30: 1245-1255
• 9 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015 26 373. 2117-2128
• 10 Kusunoki M, Sato D, Natsume Y. et al. Luseogliflozin, a sodium glucose co-transportet-2 inhibitor, alleviates hepatic impairment in Japanese patients with type 2 diabetes mellitus. Drug Research 2016; 66: 603-606
• 11 Inagaki N, Kondo K, Yoshinari T. et al. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab 2013; 15: 1136-1145
• 12 Zoppini G, Targher G, Negri C. et al. Elevated serum uric acid concentrations independently predict cardiovascular mortality in type 2 diabetic patients. Diabetes Care 2009; 32: 1716-1720
• 13 Merovci A, Solis-Herrera C, Daniele G. et al. Dapaglifrozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014; 124: 509-514
• 14 Rosenstock J, Hansen L, Zee P. et al. Dual add-on therapy in type 2 diabetes poorly controlled with metoformin monotherapy: A randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015 38. 376-383
• 15 Scheen AJ. DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: From rationale to clinical aspects. Expert Opin Drug Metab Toxicol 2016; 12: 1407-1417